Edition:
India

TB Alliance And Mylan Announce Pact To Commercialize Investigational Tuberculosis Drug


Thursday, 18 Apr 2019 

April 18 (Reuters) - Mylan NV ::TB ALLIANCE AND MYLAN ANNOUNCE GLOBAL COLLABORATION TO COMMERCIALIZE INVESTIGATIONAL DRUG PRETOMANID AS PART OF TWO REGIMENS TO TREAT TUBERCULOSIS (TB).MYLAN - TB ALLIANCE GRANTED LICENSE TO CO TO MANUFACTURE AND COMMERCIALIZE PRETOMANID FOR XDR-TB AND TREATMENT-INTOLERANT OR NON-RESPONSIVE MDR-TB.MYLAN NV - TB ALLIANCE HAS LICENSED PRETOMANID TO MYLAN FOR DS- AND MDR-TB.MYLAN NV - TB ALLIANCE GRANTED A SUBLICENSE FOR BEDAQUILINE TO MYLAN, FOR ITS DEVELOPMENT AND COMMERCIALIZATION FOR USE IN DS-TB ONLY.